Compare MSEX & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSEX | TBPH |
|---|---|---|
| Founded | 1897 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 998.7M | 1.1B |
| IPO Year | N/A | N/A |
| Metric | MSEX | TBPH |
|---|---|---|
| Price | $52.28 | $20.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $60.33 | $27.80 |
| AVG Volume (30 Days) | 100.1K | ★ 379.1K |
| Earning Date | 02-27-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ 3.71 | N/A |
| EPS | ★ 2.39 | 0.58 |
| Revenue | ★ $194,822,000.00 | $80,327,000.00 |
| Revenue This Year | $4.02 | $70.78 |
| Revenue Next Year | $8.35 | N/A |
| P/E Ratio | ★ $21.92 | $34.88 |
| Revenue Growth | 6.24 | ★ 27.12 |
| 52 Week Low | $44.17 | $7.90 |
| 52 Week High | $67.09 | $21.03 |
| Indicator | MSEX | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 60.45 |
| Support Level | $52.85 | $19.53 |
| Resistance Level | $53.98 | $21.03 |
| Average True Range (ATR) | 1.24 | 0.83 |
| MACD | 0.13 | 0.07 |
| Stochastic Oscillator | 44.92 | 76.45 |
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).